Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 platform basket study of advanced therapies for moderate to severe active Crohn's disease or ulcerative colitis
MOH_2026-08-03_016966Phase 2Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of risankizumab, tulisokibart and FG-M701 in Crohn's disease and autoimmune colitis (8 arms), sponsored by AbbVie Inc. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
risankizumabtulisokibartFG-M701
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on MOH_2026-08-03_016966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-03_016966.